Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. du Bois A, et al. Among authors: shimada m. J Clin Oncol. 2014 Oct 20;32(30):3374-82. doi: 10.1200/JCO.2014.55.7348. Epub 2014 Sep 15. J Clin Oncol. 2014. PMID: 25225436 Clinical Trial.
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Harter P, Johnson T, Berton-Rigaud D, Park SY, Friedlander M, Del Campo JM, Shimada M, Forget F, Mirza MR, Colombo N, Zamagni C, Chan JK, Imhof M, Herzog TJ, O'Donnell D, Heitz F, King K, Stinnett S, Barrett C, Jobanputra M, Xu CF, du Bois A. Harter P, et al. Among authors: shimada m. Gynecol Oncol. 2016 Mar;140(3):443-9. doi: 10.1016/j.ygyno.2015.12.027. Epub 2015 Dec 29. Gynecol Oncol. 2016. PMID: 26740259 Clinical Trial.
Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.
Shimada M, Nagao S, Fujiwara K, Takeshima N, Takizawa K, Shoji T, Sugiyama T, Yamaguchi S, Nishimura R, Kigawa J. Shimada M, et al. Int J Clin Oncol. 2016 Dec;21(6):1128-1135. doi: 10.1007/s10147-016-1010-0. Epub 2016 Jul 5. Int J Clin Oncol. 2016. PMID: 27380169 Clinical Trial.
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.
Jang JYA, Yanaihara N, Pujade-Lauraine E, Mikami Y, Oda K, Bookman M, Ledermann J, Shimada M, Kiyokawa T, Kim BG, Matsumura N, Kaku T, Kuroda T, Nagayoshi Y, Kawabata A, Iida Y, Kim JW, Quinn M, Okamoto A. Jang JYA, et al. Among authors: shimada m. J Gynecol Oncol. 2017 Jul;28(4):e54. doi: 10.3802/jgo.2017.28.e54. J Gynecol Oncol. 2017. PMID: 28541641 Free PMC article. Review.
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.
Friedlander M, Rau J, Lee CK, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, Hilpert F, King MT, Debruyne P, Bologna A, Malander S, Monk BJ, Petru E, Calvert P, Herzog TJ, Barrett C, du Bois A. Friedlander M, et al. Among authors: shimada m. Ann Oncol. 2018 Mar 1;29(3):737-743. doi: 10.1093/annonc/mdx796. Ann Oncol. 2018. PMID: 29267856 Free article. Clinical Trial.
A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
Fujiwara H, Ushijima K, Nagao S, Takei Y, Shimada M, Takano M, Yoshino K, Kawano Y, Hirashima Y, Nagase S, Nishio S, Nishikawa T, Ito K, Shoji T, Kimura E, Takano T, Sugiyama T, Kigawa J, Fujiwara K, Suzuki M. Fujiwara H, et al. Among authors: shimada m. Int J Clin Oncol. 2019 Oct;24(10):1284-1291. doi: 10.1007/s10147-019-01471-5. Epub 2019 May 24. Int J Clin Oncol. 2019. PMID: 31127479 Clinical Trial.
A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer.
Hasegawa K, Shimada M, Takeuchi S, Fujiwara H, Imai Y, Iwasa N, Wada S, Eguchi H, Oishi T, Sugiyama T, Suzuki M, Nishiyama M, Fujiwara K. Hasegawa K, et al. Among authors: shimada m. Br J Cancer. 2020 Mar;122(6):766-770. doi: 10.1038/s41416-020-0734-9. Epub 2020 Jan 31. Br J Cancer. 2020. PMID: 32001833 Free PMC article. Clinical Trial.
Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: practical biomarkers and robust multiplex models.
Kawabata-Iwakawa R, Iwasa N, Satoh K, Colinge J, Shimada M, Takeuchi S, Fujiwara H, Eguchi H, Oishi T, Sugiyama T, Suzuki M, Hasegawa K, Fujiwara K, Nishiyama M. Kawabata-Iwakawa R, et al. Among authors: shimada m. Int J Clin Oncol. 2024 Sep;29(9):1334-1346. doi: 10.1007/s10147-024-02552-w. Epub 2024 May 20. Int J Clin Oncol. 2024. PMID: 38767719
3,288 results